Table 1.
Subject characteristics.
| Groups: |
AS N = 84 (10.2%) |
AM N = 61 (7.4%) |
ECS N = 45 (5.5%) |
ECM N = 408 (49.5%) |
LCS N = 17 (2.1%) |
LCM N = 120 (14.5) |
ES N = 45 (5.5%) |
p |
|---|---|---|---|---|---|---|---|---|
| Characteristics: | ||||||||
| Age (years) Median (IQR) | 57.5 (47.5–67.2) | 36.5 (29.5–48.5) | 49 (39.25–57.5) | 37 (31–47.7) | 57 (50.5–63) | 36 (29–49) | 37 (31–51) | 0.000 |
| Female sex (N, %) | 33 (39.3%) | 29 (47.5%) | 19 (42.2%) | 252 (61.8%) | 9 (52.9%) | 80 (66.7%) | 23 (51.1%) | 0.001 |
| Days since symptoms onset Median (IQR) | 10 (7–13) | 8 (5–12) | 36 (21–48) | 38 (28–45) | 72 (64.5–88) | 80 (68–96) | 41 (24–66) | <0.0001 |
| Comorbidities (N, %) | ||||||||
| HTN | 32 (38.1%) | 5 (8.2%) | 10 (22.2%) | 30 (7.4%) | 4 (23.5%) | 6 (5%) | 4 (8.9%) | 0.000 |
| DBT | 10 (19.2%) | 2 (5%) | 5 (13.9%) | 7 (2.6%) | 0 (0.0%) | 1 (1.2%) | 3 (7.7%) | 0.000 |
| Obesity | 19 (22.6%) | 5 (8.2%) | 6 (13.3%) | 19 (4.7%) | 2 (11.8%) | 7 (5.9%) | 2 (4.4%) | 0.002 |
| DLP | 0 (0.0%) | 0 (0.0%) | 2 (4.4%) | 3 (0.7%) | 0 (0.0%) | 0 (0.0%) | 1 (2.2%) | 0.141 |
| ASTHMA | 8 (9.5%) | 2 (3.3%) | 4 (8.9%) | 12 (2.9%) | 2 (11.8%) | 3 (2.5%) | 0 (0.0%) | 0.10 |
| HIV infection | 0 (0%) | 1 (1.6%) | 1 (2.2%) | 7 (1.7%) | 2 (11.8%) | 5 (4.2%) | 0 (0.0%) | 0.01 |
| COVID TREATMENT (N, %) | 16 (20%) | 1 (1.7%) | 16 (37.2%) | 8 (2%) | 6 (40%) | 1 (0.9%) | 0 (0.0%) | 0.000 |
| POSITIVE SARS CoV2 PCR (N, %) | 84 (100.0%) | 61 (100.0%) | 40 (88.9%) | 356 (86.7%) | 16 (94.1%) | 63 (52.5%) | 0 (0.0%) | 0.000 |
| IgG anti SARSCoV2 + (N, %) | 59 (70.2%) | 22 (36.1%) | 43 (95.6%) | 292 (71.6%) | 17 (100.0%) | 96 (80.0%) | 0 (0.0%) | 0.000 |
| IgM anti SARSCoV2 + (N, %) | 57 (67.9%) | 23 (37.7%) | 37 (82.2%) | 173 (42.4%) | 9 (52.9%) | 45 (37.5%) | 0 (0.0%) | 0.000 |
AS: acute severe, AM: acute mild, ECS: early convalescent severe, ECM: early convalescent mild, LCS: late convalescent severe, LCM: late convalescent mild, ES: highly exposed SARS-CoV-2 seronegative contacts, HTN: arterial hypertension, DBT: diabetes, DLP: dyslipidemia.